DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Stintzing S. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Lancet Oncol 2016;
17: 1426-1434

Download Bibliographical Data

Search in:
Access: